Clinical Trial Update: Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, tolerability, and antiviral activity of GS-9190 in combination with peginterferon alfa-2a and ribavirin for genotype-1 chronic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GS-9190
• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Gilead Sciences | Conditions: HCV Infection | Phase 2 | Status: COMPLETED